PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.
10x Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences. On February 25, 2025, a consent agreement was ...